Home
ZBIO
ZBIO News

Latest ZENAS BIOPHARMA INC (ZBIO) News on June 5, 2025

Zenas BioPharma to Present at the Jefferies Global Healthcare Conference

GlobeNewswire

7 days ago

Zenas BioPharma to Present at the Jefferies Global Healthcare Conference

Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates

GlobeNewswire

21 days ago

Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Zenas BioPharma Insiders US$407k Short Of Breakeven On Stock Purchase

Simply Wall St.

a month ago

Zenas BioPharma Insiders US$407k Short Of Breakeven On Stock Purchase

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer

GlobeNewswire

2 months ago

Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer

Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress

Benzinga

3 months ago

Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress

MT Newswires

3 months ago

Wedbush Initiates Zenas BioPharma at Outperform With $35 Price Target

Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

GlobeNewswire

3 months ago

Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

Is Zenas BioPharma (NASDAQ:ZBIO) In A Good Position To Invest In Growth?

Simply Wall St.

3 months ago

Is Zenas BioPharma (NASDAQ:ZBIO) In A Good Position To Invest In Growth?

Argus Research

4 months ago

Daily – Vickers Top Buyers & Sellers for 02/20/2025

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

GlobeNewswire

4 months ago

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

MT Newswires

4 months ago

Wolfe Research Initiates Coverage on Zenas BioPharma With Outperform Rating, $19 Price Target

Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference

GlobeNewswire

4 months ago

Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference

Zenas BioPharma initiated with a Buy at H.C. Wainwright

TipRanks

6 months ago

Zenas BioPharma initiated with a Buy at H.C. Wainwright

MT Newswires

6 months ago

HC Wainwright Initiates Zenas BioPharma at Buy With $30 Price Target

Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley

TipRanks

6 months ago

Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley

Argus Research

6 months ago

Daily – Vickers Top Buyers & Sellers for 12/05/2024

Argus Research

6 months ago

Daily – Vickers Top Buyers & Sellers for 11/21/2024

Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire

7 months ago

Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

GlobeNewswire

7 months ago

Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences

GlobeNewswire

7 months ago

Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences

Opening Day: Another trio of biotech IPOs make Friday debut

TipRanks

8 months ago

Opening Day: Another trio of biotech IPOs make Friday debut

Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering

GlobeNewswire

9 months ago

Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering

Share on Social Networks: